RMD Open最新文献

{"title":"Instruments for measuring fatigue in people with rheumatic and musculoskeletal diseases: a systematic review of measurement properties.","authors":"Eduardo José Ferreira Santos, Bayram Farisogullari, Katie Fishpool, George Young, Coziana Ciurtin, Fiona Cramp, Emmanuel Oghenetejiri Erhieyovwe, Gary J Macfarlane, Jen Pearson, Emma Dures, Pedro M Machado","doi":"10.1136/rmdopen-2025-006079","DOIUrl":"https://doi.org/10.1136/rmdopen-2025-006079","url":null,"abstract":"<p><strong>Objective: </strong>To summarise the measurement properties of instruments used to assess fatigue in people with rheumatic and musculoskeletal diseases (RMDs).</p><p><strong>Methods: </strong>A systematic review (SR) of measurement properties was conducted in children, adolescents/young adults and adults with RMDs, following Joanna Briggs Institute and COSMIN (COnsensus-based Standards for the selection of health Measurement INstruments) guidelines. Searches were performed in Medline, Embase, CINAHL and Cochrane Library. Risk of bias assessment, data extraction and synthesis were conducted independently by two reviewers. Instruments were assessed according to Outcome Measures in Rheumatology (OMERACT) criteria.</p><p><strong>Results: </strong>Out of 16 657 records, 109 articles underwent full-text review, and 60 met inclusion criteria. These studies evaluated the psychometric properties of 27 instruments. Most studies focused on construct validity (54/60, 90%) and intermethod reliability (45/60, 75%), with an overall low risk of bias. In contrast, test-retest reliability (13/60, 21.7%) and responsiveness (14/60, 23.3%) were less frequently assessed, but also with an overall low risk of bias. Evidence regarding clinical trial discrimination and thresholds of meaningful change was limited or absent, indicating the need for further research in these domains. Only five instruments-the Functional Assessment of Chronic Illness Therapy (FACIT) Fatigue, the 36-Item Short Form Survey Instrument (SF-36) Vitality, the Bristol Rheumatoid Arthritis Fatigue Multi-Dimensional Questionnaire (BRAF-MDQ), the BRAF Numerical Rating Scales (BRAF-NRS) and the Fatigue Severity Scale (FSS)-were rated as valid, reliable and low risk of bias, fulfilling OMERACT endorsement criteria.</p><p><strong>Conclusions: </strong>This SR comprehensively supports the use of several well-validated instruments to assess fatigue, particularly FACIT-Fatigue, SF-36 Vitality, BRAF-MDQ, BRAF-NRS and FSS, in both clinical and research settings.</p><p><strong>Prospero registration number: </strong>CRD42024507112.</p>","PeriodicalId":21396,"journal":{"name":"RMD Open","volume":"11 4","pages":""},"PeriodicalIF":4.7,"publicationDate":"2025-10-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145368746","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Unravelling IPAF, VEDOSS and connective tissue diseases classifications through the mixed connective tissue disease spectrum.","authors":"Kevin Chevalier, Benjamin Thoreau, Marc Michel, Bertrand Godeau, Christian Agard, Thomas Papo, Karim Sacre, Brigitte Bader-Meunier, Raphaele Seror, Xavier Mariette, Patrice Cacoub, Ygal Benhamou, Hervé Levesque, Cécile Goujard, Olivier Lambotte, Bernard Bonnotte, Maxime Samson, Félix Ackermann, Jean Schmidt, Pierre Duhaut, Isabelle Koné-Paut, Jean-Emmanuel Kahn, Thomas Hanslik, Nathalie Costedoat-Chalumeau, Benjamin Terrier, Alexis Regent, Bertrand Dunogue, Pascal Cohen, Véronique Le Guern, Eric Hachulla, Benjamin Chaigne, Luc Mouthon","doi":"10.1136/rmdopen-2025-006145","DOIUrl":"https://doi.org/10.1136/rmdopen-2025-006145","url":null,"abstract":"<p><strong>Background: </strong>Mixed connective tissue disease (MCTD) has long been debated as an early nonspecific phase/symptom of differentiated connective tissue diseases (dCTD), similarly to interstitial pneumonia with autoimmune features (IPAF) and very early diagnosis of systemic sclerosis (SSc) (VEDOSS).</p><p><strong>Objective: </strong>We aimed to evaluate the predictive value of IPAF, VEDOSS and dCTD classification criteria variables in MCTD patients.</p><p><strong>Methods: </strong>We conducted an observational study within the French MCTD cohort. IPAF, VEDOSS and current dCTD classification criteria were used to classify patients.</p><p><strong>Results: </strong>Three hundred and twenty-four MCTD patients were included and followed for 8 (3.3-13) years. Among them, 111 (34.3%) progressed into a dCTD, that is, 50 (15.4%) SSc, 40 (12.3%) systemic lupus erythematosus (SLE) and 11 (3.4%) Sjögren's disease. At diagnosis, 38 (11.7%) patients fulfilled IPAF criteria, among which 15 (39.5%) progressed into a dCTD (vs 75 (26.2%) in patients who did not fulfil IPAF criteria; p=0.09). At diagnosis, 293 (90.4%) patients fulfilled VEDOSS criteria but did not progress significantly more frequently to SSc than MCTD patients without VEDOSS criteria (46 (15.7%) vs 4 (12.9%); p=0.8). At baseline, SSc classification criteria did not predict evolution toward SSc, whereas antiphospholipid antibodies and low C3 and/or C4 were predictive of an evolution toward SLE (p=0.01 and p=0.04, respectively).</p><p><strong>Conclusion: </strong>At MCTD diagnosis, fulfilment of IPAF and/or VEDOSS criteria was not predictive of evolution toward SSc, whereas antiphospholipid antibodies and low C3 and/or C4 were predictive of an evolution toward SLE. This suggests that MCTD patients should be excluded from IPAF and VEDOSS.</p>","PeriodicalId":21396,"journal":{"name":"RMD Open","volume":"11 4","pages":""},"PeriodicalIF":4.7,"publicationDate":"2025-10-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145355910","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Ultrasound-guided core needle biopsy of the parotid gland in Sjögren's disease: a promising tool towards precision medicine.","authors":"Helena Achten, Eva Genbrugge, Liselotte Deroo, David Creytens, Amber Vanhaecke, Joke Deprez, Emilie Dumas, Sophie Vanhoof, Kristel De Boeck, Wouter Bauters, Frederick Dochy, Dimitri Roels, Dirk Elewaut, Isabelle Peene","doi":"10.1136/rmdopen-2025-005560","DOIUrl":"https://doi.org/10.1136/rmdopen-2025-005560","url":null,"abstract":"<p><strong>Background: </strong>Disappointing outcomes in Sjögren's disease (SjD) trials underscore the need for reliable, sensitive endpoints. Histological assessment holds promise, but a minimally invasive, repeatable method for salivary gland tissue sampling is lacking.</p><p><strong>Objectives: </strong>To evaluate the feasibility, safety and tissue adequacy of ultrasound-guided core needle biopsy (US-guided CNB) of the parotid gland and explore its role for facilitating histology-driven stratification and precision medicine.</p><p><strong>Methods: </strong>In the Belgian Sjögren's Syndrome Transition Trial, 66 patients (64 without gland swelling) underwent US-guided CNB. US was evaluated using OMERACT (Outcome Measures in Rheumatology Clinical Trials). and Hocevar scoring. Histopathology included assessment of focus score, B cell predominance (CD20>CD3), follicular dendritic cell networks (CD21), plasma cells (CD138), lymphoepithelial lesions (CK7/CK14) and FcRL4+ B cells. Pain was assessed using a visual analogue scale (VAS) from 0 to 10. Findings were matched with clinical data.</p><p><strong>Results: </strong>Mean VAS pain scores were 2.7 (SD=2.77) during biopsy and 1.9 (SD=2.33) in the 3 days before the follow-up call at day 14. No major complications occurred, and 82% of patients were willing to repeat the procedure. Adequate tissue was retrieved in 62/66 cases. Patients showed histological heterogeneity and were, as proof of concept, stratified into mild, moderate and severe histological involvement. Histological severity correlated with ultrasound scores (p<0.01) and not with traditional outcome measures (European Alliance of Associations for Rheumatology Sjögren's Syndrome Patient-Reported Index dryness and European Alliance of Associations for Rheumatology Sjögren's Syndrome Disease Activity Index).</p><p><strong>Conclusion: </strong>US-guided CNB is safe, well-tolerated and yields adequate tissue. Beyond diagnostics, it might facilitate histology-driven patient stratification and advance precision medicine for SjD.</p>","PeriodicalId":21396,"journal":{"name":"RMD Open","volume":"11 4","pages":""},"PeriodicalIF":4.7,"publicationDate":"2025-10-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145368716","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Targeted proteomics identifies differentially expressed proteins in Sjögren's disease with incident lymphoma.","authors":"Juliana Imgenberg-Kreuz, Cecilia Fugmann, Anna-Maja Molin, Carin Backlin, Alina Johansson, Milica Vranic, Anna Nikkarinen, Per Eriksson, Christopher Sjöwall, Eva Baecklund, Gunnel Nordmark","doi":"10.1136/rmdopen-2025-005897","DOIUrl":"https://doi.org/10.1136/rmdopen-2025-005897","url":null,"abstract":"<p><strong>Objectives: </strong>Patients with primary Sjögren's disease (SjD) have an increased risk of B cell lymphoma. The aim of this study was to determine serum protein biomarkers for lymphoma development and to advance our understanding of the functional mechanisms underlying lymphomagenesis in SjD.</p><p><strong>Methods: </strong>Patients with SjD and incident, current lymphoma (n=18) with serum sampled before treatment and at 6, 12 and 24 months of follow-up, and four patients sampled 1-5 years before lymphoma diagnosis (pre-lymphoma) were included. SjD without lymphoma (n=21), SjD with historical lymphoma (n=6) and healthy blood donors (n=39) served as controls. Differentially expressed proteins between groups were analysed using the Olink Target 96 Immuno-Oncology panel applying a false discovery rate (FDR) adjusted p value of 0.05. Protein-derived interferon activation scores (pIFN scores) were calculated.</p><p><strong>Results: </strong>We determined 18 differentially expressed proteins in SjD with incident lymphoma compared with both SjD without lymphoma and healthy controls. Among the top upregulated proteins were TNFSF14, FGF2, IL8, CD40 and CXCL13, where CXCL13 was the only protein with decreased levels at follow-up. We also observed upregulated expression of CD40 in the SjD pre-lymphoma group compared with SjD without lymphoma and healthy controls. All SjD patient groups presented elevated pIFN scores compared with healthy controls, where SjD sampled pre-lymphoma showed the most distinct IFN activation.</p><p><strong>Conclusions: </strong>We identified altered protein expression and an increased IFN system activation in SjD with incident lymphoma and pre-lymphoma. This knowledge may contribute to earlier detection of high-risk patients, identification of therapeutic targets and may ultimately improve SjD patient outcomes.</p>","PeriodicalId":21396,"journal":{"name":"RMD Open","volume":"11 4","pages":""},"PeriodicalIF":4.7,"publicationDate":"2025-10-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145355891","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Sustained resolution of enthesitis and peripheral arthritis over 104 weeks with bimekizumab in axial spondyloarthritis.","authors":"Sofia Ramiro, Denis Poddubnyy, Philip J Mease, Clementina López-Medina, Mindy Kim, Ute Massow, Vanessa Taieb, Tue Wenzel Kragstrup, Dennis McGonagle","doi":"10.1136/rmdopen-2025-005969","DOIUrl":"https://doi.org/10.1136/rmdopen-2025-005969","url":null,"abstract":"<p><strong>Background: </strong>Bimekizumab (BKZ), a monoclonal IgG1 antibody that selectively inhibits interleukin (IL)-17F in addition to IL-17A, has demonstrated 2-year efficacy in non-radiographic axial spondyloarthritis (nr-axSpA) and radiographic axSpA (r-axSpA) phase III studies.</p><p><strong>Objective: </strong>Assess the impact of BKZ on peripheral manifestations to week 104 of those studies.</p><p><strong>Methods: </strong>BE MOBILE 1 (nr-axSpA) and 2 (r-axSpA) each comprised a 16-week double-blind, placebo-controlled period, then all received BKZ 160 mg every 4 weeks for 36 weeks. Patients not meeting withdrawal criteria could enter a combined open-label extension. We report change in enthesitis (Maastricht Ankylosing Spondylitis Enthesitis Score (MASES)) in patients with baseline MASES>0, peripheral arthritis (swollen joint count (SJC)/Disease Activity Index for Psoriatic Arthritis (DAPSA)) in patients with baseline SJC>0 and proportions achieving DAPSA disease states to week 104. Resolution of enthesitis (MASES=0)/arthritis (SJC=0) is reported to week 104 for those with baseline enthesitis/arthritis. We also report associations between peripheral manifestation resolution (MASES=0/SJC=0) and week 104 clinical outcomes in those with baseline enthesitis/arthritis.</p><p><strong>Results: </strong>At baseline, 186/254 (73.2%) and 88/254 (34.6%) patients with nr-axSpA had enthesitis (MASES>0) and arthritis (SJC>0), respectively, compared with 199/332 (59.9%) and 66/332 (19.9%) patients with r-axSpA. Pooled BKZ/placebo-randomised patients with enthesitis (nr-axSpA/r-axSpA) showed average MASES improvement from 4.8/4.3 (baseline) to 1.6/1.3 (week 52) and 1.6/1.0 (week 104). Pooled BKZ/placebo-randomised patients with arthritis showed average SJC improvement from 4.0/4.5 (baseline) to 1.2/0.7 (week 52) and 0.9/0.6 (week 104). Over 60% of patients achieved DAPSA low disease activity/remission by week 52. Over 40%/60% patients achieved resolution of enthesitis (MASES=0)/arthritis (SJC=0) at week 104; enthesitis resolution was associated with larger improvements in week 104 clinical outcomes for patients with r-axSpA.</p><p><strong>Conclusion: </strong>BKZ resulted in sustained improvements in peripheral manifestations to 2 years across the full disease spectrum of axSpA.</p>","PeriodicalId":21396,"journal":{"name":"RMD Open","volume":"11 4","pages":""},"PeriodicalIF":4.7,"publicationDate":"2025-10-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145346860","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impaired cardiorespiratory fitness in psoriatic arthritis: insights from cardiopulmonary exercise testing.","authors":"Marlies Kaerts, Kurt de Vlam, Rik Lories, Barbara Neerinckx, Thijs Willem Swinnen","doi":"10.1136/rmdopen-2025-006110","DOIUrl":"10.1136/rmdopen-2025-006110","url":null,"abstract":"<p><strong>Background: </strong>Data on cardiorespiratory fitness (CRF) in psoriatic arthritis (PsA) are scarce. This study aimed to determine the CRF level in patients with PsA and to examine the relation between CRF and disease parameters, cardiometabolic risk profile as well as patient-reported outcome measures (PROMs).</p><p><strong>Methods: </strong>In this cross-sectional study, CRF was measured as peak oxygen uptake (VO₂peak) during an incremental maximal cardiopulmonary exercise test and compared with reference charts of the general population using the one-sided t-test. Multivariable linear regression models were built to evaluate the associations between VO₂peak (mL/min/kg, log-transformed) and disease parameters, cardiometabolic risk parameters and PROMs. Statistical significance was defined as p<0.05 with application of Holm-Bonferroni correction in regression analysis (expressed as p*).</p><p><strong>Results: </strong>In 80 patients with PsA (41% females, mean age 51 years (SD=11)), mean VO₂peak was 26.03 mL/min/kg (SD=7.56) and significantly decreased compared with the physically active reference population (mean 74.01% (SD=19.19), p<0.001) with 41% having an impaired CRF. In the final multivariable linear regression model, adjusted for age and sex, disease activity (Psoriatic Arthritis Disease Activity Score: β=-0.2757, p*=0.009), waist-hip ratio (β=-0.4193, p*<0.001), patient-reported disease impact (Psoriatic Arthritis Impact of Disease 12-item questionnaire: β=-0.2385, p*=0.015), and moderate-to-vigorous physical activity during commuting and leisure time (minutes/week: β=0.1702, p*=0.015) were significantly associated with VO₂peak (adjusted R²=0.71).</p><p><strong>Conclusions: </strong>The CRF level of patients with PsA was significantly decreased compared to a physically active population with 41% having an impaired CRF. A lower CRF level was substantially associated with impaired disease control, unfavourable body composition, lower self-reported physical activity as well as with higher patient-reported disease impact.</p>","PeriodicalId":21396,"journal":{"name":"RMD Open","volume":"11 4","pages":""},"PeriodicalIF":4.7,"publicationDate":"2025-10-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12542730/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145346923","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Predictors of a successful glucocorticoid tapering and withdrawal in an inception cohort of patients with lupus nephritis and associations with long-term outcomes and damage accrual.","authors":"Ioannis E Michelakis, Alexandros Panagiotopoulos, Eleni Kapsia, John Boletis, Smaragdi Marinaki, Petros P Sfikakis, Maria G Tektonidou","doi":"10.1136/rmdopen-2025-005877","DOIUrl":"10.1136/rmdopen-2025-005877","url":null,"abstract":"<p><strong>Objectives: </strong>The optimal duration of glucocorticoid (GC) treatment in lupus nephritis (LN) remains unclear. We examined predictors of GC tapering and discontinuation (D/C), flares during tapering and post-D/C and long-term outcomes.</p><p><strong>Methods: </strong>We analysed inception cohort data (1992-2021) from 136 patients with LN (median follow-up: 121 months) and applied regression models to assess predictors of successful GC D/C and long-term outcomes, including clinical/laboratory, histological and treatment characteristics.</p><p><strong>Results: </strong>Median time to 7.5 mg/day, 5 mg/day and GC D/C was 9, 12 and 29 months post-diagnosis, respectively. Composite complete renal response (CR) and Systemic Lupus Erythematosus Disease Activity Index (SLEDAI)-2K≤4, sustainedly attained until GC D/C (HR: 1.85, p=0.016), membranous LN (HR: 1.81, p=0.01) and persistent use of hydroxychloroquine (HR: 1.49, p=0.04) were associated with a shorter time to GC D/C. Patients diagnosed after 2010 achieved earlier GC D/C.Shorter time to CR (OR: 1.05, p=0.034) and Lupus Low Disease Activity State at tapering from 7.5 mg/day onwards (OR: 0.23, p=0.046) reduced flare risk during tapering. Definition Of Remission In Systemic Lupus Erythematosus (DORIS) complete remission at D/C (OR: 0.20, p=0.005) and persistent hydroxychloroquine use (OR: 0.28, p=0.031) protected against post-D/C renal flares. Neither higher initial GC dose (>40 mg/day) nor slower GC tapering prevented renal flares. Time to GC D/C (OR: 1.02/month, p=0.04) and flares (OR: 2.08, p=0.036) were associated with damage risk at the end of follow-up.</p><p><strong>Conclusion: </strong>Sustained CR/SLEDAI-2K≤4, membranous LN and persistent hydroxychloroquine use emerged as main predictors of shorter time to D/C, while DORIS complete remission at D/C and persistent hydroxychloroquine use predicted post-DC flares. Time to GC D/C and flares independently contributed to 10-year damage accrual.</p>","PeriodicalId":21396,"journal":{"name":"RMD Open","volume":"11 4","pages":""},"PeriodicalIF":4.7,"publicationDate":"2025-10-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12542714/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145346925","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Nailfold capillaroscopy in patients with systemic sclerosis-associated interstitial lung disease: a substudy of the SENSCIS trial.","authors":"Vanessa Smith, Christopher P Denton, Ariane L Herrick, Carina Ittrich, Margarida Alves, Maurizio Cutolo","doi":"10.1136/rmdopen-2025-005704","DOIUrl":"10.1136/rmdopen-2025-005704","url":null,"abstract":"<p><strong>Objective: </strong>To assess microvascular changes in nailfold capillaries in patients with systemic sclerosis-associated interstitial lung disease (SSc-ILD) who received nintedanib or placebo in a sub-study of the SENSCIS trial.</p><p><strong>Methods: </strong>Nailfold capillaroscopy (NC) was performed at baseline and week 52. In the nintedanib and placebo groups, we measured capillary density (number of capillaries/mm), giant capillaries, abnormal shapes and percentage of fingers with microhaemorrhages. In addition, capillary density was evaluated in patients who did/did not have risk factors for rapid forced vital capacity (FVC) decline at baseline and who did/did not have ILD progression (absolute decline in FVC % predicted >5% or death) from baseline to week 52.</p><p><strong>Results: </strong>Between baseline and week 52, no notable changes were observed in any NC measurement in the overall placebo or nintedanib groups. In patients with risk factors for rapid FVC decline (n=38), there was a numerical reduction in mean capillary density over 52 weeks with placebo, but it remained stable with nintedanib. Among patients who had ILD progression (n=11), there was a numerical increase in mean capillary density over 52 weeks with nintedanib, but it remained stable with placebo. There were no notable changes in capillary density among patients who did not have risk factors for rapid FVC decline at baseline or ILD progression at week 52.</p><p><strong>Conclusion: </strong>In a substudy of the SENSCIS trial, numerical differences in changes in capillary density assessed by NC over 52 weeks may suggest a potential effect of nintedanib in patients at risk of ILD progression.</p>","PeriodicalId":21396,"journal":{"name":"RMD Open","volume":"11 4","pages":""},"PeriodicalIF":4.7,"publicationDate":"2025-10-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12542725/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145313411","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Utility of repeat MRI in assessing treatment non-response in axial spondyloarthritis: data from two large tertiary rheumatology centres.","authors":"Jake Weddell, Ayaan Farah, Rahul Shah, Lara Rossi, Sophia Lekh, Sabrin Mohamud, Philip Robinson, Jane E Freeston, Andrew Barr, Vandevelde Y Claire, Denis Remedios, Dennis McGonagle, Pedro M Machado, Helena Marzo-Ortega","doi":"10.1136/rmdopen-2025-005925","DOIUrl":"10.1136/rmdopen-2025-005925","url":null,"abstract":"<p><strong>Introduction: </strong>The role of MRI of the spine/sacroiliac joints to aid the diagnosis of axial spondyloarthritis (axSpA) is well established. Limited data, however, exist on the use of MRI to assess disease activity, resulting in current Assessment of SpondyloArthritis International Society (ASAS)/European Alliance of Associations for Rheumatology (EULAR) guidelines not recommending the use of MRI for this purpose. We aimed to assess the current use of MRI to assess disease activity and its impact on clinical decision making.</p><p><strong>Methods: </strong>As part of a service evaluation, we identified patients with a prior diagnosis of axSpA, who had an MRI of the spine/sacroiliac joints requested between May 2020 and December 2023 at The Leeds Teaching Hospitals Trust (Leeds) and Northwick Park Hospital (London). Clinical and demographic data were extracted from the medical notes. Data on MRI findings were extracted from the radiologist's report.</p><p><strong>Results: </strong>Overall, 346 scans were performed in 335 patients. 301 patients had axSpA (170 radiographic axSpA, 131 non-radiographic axSpA) and 31 axial psoriatic arthritis. Patients were predominantly male (60.0%) and HLA-B27 positive (60.6%). 140/172 (80.1%) of patients had evidence of inflammation on a pre-treatment MRI scan. 224 scans (64.7%) were performed in patients on biologic/targeted synthetic disease-modifying antirheumatic drugs. Of the 346 MRIs performed during the audit period, 179 (54.7%) had evidence of active inflammation and those with active inflammation were more likely to have their treatment escalated (59.3% vs 23.2%).</p><p><strong>Conclusions: </strong>MRI is of utility in assessing disease activity with results of MRI scans directly influencing treatment decision making at the bedside. Further research exploring the relationship between MRI findings and clinical outcomes is warranted.</p>","PeriodicalId":21396,"journal":{"name":"RMD Open","volume":"11 4","pages":""},"PeriodicalIF":4.7,"publicationDate":"2025-10-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12542750/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145313453","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Multiple DMARD discontinuations in rheumatoid arthritis: how often and in what patients? Results from a national clinical RA register.","authors":"Emma Wettersand, Daniela di Giuseppe, Johan Askling, Katerina Chatzidionysiou","doi":"10.1136/rmdopen-2025-005617","DOIUrl":"10.1136/rmdopen-2025-005617","url":null,"abstract":"<p><strong>Objectives: </strong>Multiple discontinuations of biologic (b-) or targeted synthetic (ts-) disease-modifying antirheumatic drugs (DMARDs) may indicate difficult-to-treat disease. We aimed to assess the occurrence of b/tsDMARD discontinuations in patients with rheumatoid arthritis (RA), specifically how this varies by definition, across patient subsets and over time.</p><p><strong>Methods: </strong>Observational cohort study using data from the Swedish Rheumatology Quality Register on patients diagnosed with RA between 2010 and 2019. We identified three populations: (1) newly diagnosed (N=17 780), (2) initiating a first-ever DMARD (N=18 038) and (3) initiating a first-ever b/tsDMARD (N=8075). In each, we assessed the proportions and characteristics of patients fulfilling either of seven alternative DMARD discontinuation criteria (each encompassing a unique combination of number and type(s) of b/tsDMARD).</p><p><strong>Results: </strong>At 4.5 years of follow-up, 10% in populations (1) and (2), and 25% in (3), had discontinued ≥2 b/tsDMARDs with different modes of action. The proportions meeting each of the other six definitions ranged from 0.3% to 10% in (1) and (2), and 1% to 25% in (3). Regardless of definition or time, the characteristics of discontinuers across populations (1) through (3) remained largely similar.</p><p><strong>Conclusions: </strong>Applying treatment discontinuation-based definitions to an unselected RA population identifies widely varying proportions of patients with largely similar characteristics. Quantitatively, treatment-based definitions, follow-up time and study population must be clearly specified; qualitatively, the specific definition may be less critical.</p>","PeriodicalId":21396,"journal":{"name":"RMD Open","volume":"11 4","pages":""},"PeriodicalIF":4.7,"publicationDate":"2025-10-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12530398/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145302868","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}